Does an AI drug repurposing prediction establish a new treatment?

Understanding the question

No. An AI drug repurposing prediction proposes a relationship worth investigating; it does not establish efficacy, an appropriate dose or safety for a new indication. Models can connect molecular signatures, known targets and disease-related data to rank candidates for research. The evidence behind those connections varies, and a compound that affects a pathway in a laboratory system may not reach the relevant tissue at a tolerable exposure. Existing approval for one use does not automatically transfer to another population or condition. Clinical conclusions require suitable studies and regulatory evaluation, not computational ranking alone.

What a useful investigation needs to consider

Inspect the evidence chain behind each candidate, including target relevance, direction of effect and the biological system in which the relationship was observed. Similarity between molecular signatures can have multiple explanations and is not a substitute for functional confirmation.

Consider tissue exposure, interactions, contraindications and differences between the original and proposed patient populations. Keep research prioritization separate from medical advice. A useful computational result narrows a scientific question and identifies what evidence is missing, rather than presenting an approved medicine as an established treatment for an untested use.

Read the detailed explanation

The companion article explores ai drug repurposing: evaluating a ranked hypothesis in more depth, with topic-specific explanations and source material.